Sun Pharmaceutical Industries Limited announced that a U.S. court has ruled in its favour, lifting a preliminary injunction and allowing it to launch LEQSELVI, a drug used to treat an autoimmune disorder that causes patchy hair loss.

Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI. On April 9, 2025, the U.S. Court of Appeals for the Federal Circuit heard Sun Pharma’s appeal against a preliminary injunction earlier issued by the U.S. District Court for the District of New Jersey.

On 9 April 2025, the US Court of Appeals for the Federal Circuit held an oral argument on the company’s appeal of the US District Court for the District of New Jersey’s decision that previously granted a preliminary injunction delaying the company’s launch of LEQSELVI (deuruxolitinib) in the United States.

”Shortly after the oral argument concluded, on 9th April 2025, the US Court of Appeals for the Federal Circuit ruled in favour of the company and vacated the preliminary injunction effective immediately. While the litigation between Incyte Corporation and the company continues, the preliminary injunction is no longer in effect. The company is no longer under a court order that delays or restricts the company from launching LEQSELVI. The company will disclose LEQSELVI launch plans in due course of time. This is further to our intimation dated 2nd November 2024,” Sun Pharma said.